Aktienanalyse zu Mirion Technologies Inc (MIR)MIRMirion Technologies Inc

Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).

Mirion Technologies Inc is not a good buy right now due to its current price of $14.40, which is significantly below analyst price targets ranging from $22 to $27, indicating potential further downside. The RSI is at 28.453, suggesting the stock is oversold, but the recent insider selling and a year-to-date decline of 39.57% raise concerns about future performance. The main risk is the high P/E ratio of 149.73, indicating that the stock may be overvalued relative to its earnings potential.